达石药业

Dashi Pharma is a clinical-stage biopharmaceutical company headquartered in Zhongshan, China, focused on developing innovative antibody drugs for pain management and oncology. The company's lead candidate, DS002, is a humanized monoclonal antibody targeting Nerve Growth Factor (NGF) currently in Phase 2 clinical trials for osteoarthritis and cancer pain. Dashi Pharma also has a robust pipeline including DS005, which targets Calcitonin Gene-Related Peptide (CGRP) for migraine prevention. By utilizing its proprietary antibody engineering platforms, the company aims to address significant unmet medical needs in the global pain market. The leadership team consists of industry veterans with extensive experience in antibody drug discovery and clinical development. Dashi Pharma has secured significant venture capital funding to advance its clinical programs and expand its R&D capabilities.